High-grade glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Stupp, Roger; Brada, Michael; Bent, Martin J. van den; Tonn, Jörg C.; Pentheroudakis, George

doi:10.1093/annonc/mdu050

Cited by 640 publications

(507 citation statements)

References 70 publications

Supporting

Mentioning

481

Contrasting

Unclassified

Order By: Relevance

“…34 Due to its infiltrating nature, HGG cannot be completely excised and in most cases recurs locally. 14 Given the high level of heterogeneity and inaccuracy of traditional clinicopathological factors such as age, grade, KPS score, and tumor resection for predicting prognosis, the identification of molecular markers in HGG that can help to distinguish among patients with different prognoses or clinical responses to specific therapies is essential.…”

Section: Discussionmentioning

confidence: 99%

Association between small heat shock protein B11 and the prognostic value of MGMT promoter methylation in patients with high-grade glioma

Cheng

Jiang

et al. 2016

JNS

View full text Add to dashboard Cite

G lioma is the most common type of tumor in the CNS. The WHO classifies glioma on a scale of Grades I-IV, according to histopathologic features. 28 Grades III and IV are progressive, resistant to treatment, and grouped together as high-grade glioma (HGG) for the purposes of clinical management. Glioblastoma and anaplastic glioma comprise the majority of HGG cases. Since the incorporation of alkylating agents such as temozolomide (TMZ) into routine chemotherapy, the prognosis for patients with HGG has significantly improved. The epigenetic silencing of O 6 -methylguanine-DNA methyltransferase (MGMT) (which encodes a DNA repair protein) by promoter methylation is associated with favorable prognosis in patients with HGG. 35,40,41 Numerous studies have also shown that MGMT promoter methylation can be used to predict the extent to which patients abbreviatioNs CGGA = Chinese Glioma Genome Atlas; GBM = glioblastoma; GO = gene ontology; GSEA = Gene Set Enrichment Analysis; HGG = high-grade glioma; HSP = heat shock protein; IDH1 = isocitrate dehydrogenase 1; KPS = Karnofsky Performance Scale; LGG = low-grade glioma; MGMT = O 6 -methylguanine-DNA methyltransferase; mRNA = messenger RNA; OS = overall survival; PCR = polymerase chain reaction; PFS = progression-free survival; REMBRANDT = Repository for Molecular Brain Neoplasia Data; SAM = significance analysis of microarrays; TMZ = temozolomide. results Of 28 HSPs, 11 were overexpressed in high-grade glioma (HGG) compared with low-grade glioma. A univariate Cox analysis revealed that HSPB11 has significant prognostic value for each glioma grade, which was validated by a Kaplan-Meier survival analysis. HSPB11 expression was associated with poor prognosis and was independently correlated with overall survival (OS) in HGG. This study further explored the combined role of HSPB11 and other molecular markers in HGG, such as isocitrate dehydrogenase 1 (IDH1) mutation and O 6 -methylguanine-DNA methyltransferase (MGMT) promoter methylation status. HSPB11 expression was able to refine the prognostic value of IDH1 mutation in patients with HGG. However, when combined with MGMT promoter methylation status, among patients with a methylated MGMT promoter, those with lower levels of HSPB11 expression had longer OS and progression-free survival than patients with higher levels of HSPB11 expression or with an unmethylated MGMT promoter. Moreover, within the MGMT promoter methylation group, patients with low levels of HSPB11 expression were more sensitive to combined radiochemotherapy than those with high levels of HSPB11 expression, which may explain why some patients with HGG with a methylated MGMT promoter show tolerance to radiochemotherapy. coNclusioNs HSPB11 was identified as a novel prognostic marker in patients with HGG. Together with MGMT promoter methylation status, HSPB11 expression can predict outcome for patients with HGG and identify those who would most benefit from combined radiochemotherapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Association between small heat shock protein B11 and the prognostic value of MGMT promoter methylation in patients with high-grade glioma

Cheng

Jiang

et al. 2016

JNS

View full text Add to dashboard Cite

show abstract

“…Так, на них приходится до 70% всех видов злокачественных новообразований головного мозга [5,6], при этом опухоли головного мозга находятся на 3-м ме-сте по темпам роста заболеваемости среди всех онколо-гических новообразований [7]. Ежегодно заболеваемость злокачественными глиомами составляет 3-5 случаев на 100 000 населения с небольшим преобладанием лиц мужского пола [6,8]. При этом следует отметить, что для глиом не исключается прогрессия заболевания в более высокий класс анаплазии [9].…”

Section: ключевые слова: анапластическая астроцитома глиомы бевацизunclassified

Modern tactics of treatment of malignant glyom of the brain and the case of the complete answer of the tumor on the background of the long-term reception of bevacizumab

et al. 2017

View full text Add to dashboard Cite

“…The incidence of HGG is less than 5 per 100,000 people a year [1], which is approximately 1 % of all newly diagnosed cancers. Total resection can be a definite treatment for HGG [2], and chemo-radiotherapy using temozolomide is commonly used as an adjuvant treatment [3].…”

Section: Introductionmentioning

confidence: 99%

“…However, HGG is very infiltrative, and complete resection is unavailable in most cases. The majority of HGG recurs within 1 year after initial treatment, and overall survival from HGG is very poor, despite the standard treatment [1]. For prognostication of HGG, age, pathologic type, Karnofsky performance status (KPS) score and genetic mutation patterns have been suggested as prognostic factors [4,5].…”

Section: Introductionmentioning

confidence: 99%

Prognostic Value of Metabolic Tumor Volume on 11C-Methionine PET in Predicting Progression-Free Survival in High-Grade Glioma

Yoo

Paeng

Cheon

et al. 2015

Nucl Med Mol Imaging

View full text Add to dashboard Cite

Purpose C-11 methionine (MET) PET is commonly used for diagnosing high-grade glioma (HGG). Recently, volumetric analysis has been widely applied to oncologic PET imaging. In this study, we investigated the prognostic value of metabolic tumor volume (MTV) on MET PET in HGG. Methods A total of 30 patients with anaplastic astrocytoma (n=12) and glioblastoma multiforme (n=18) who underwent MET PET before treatment (surgery followed by chemoradiotherapy) were retrospectively enrolled. Maximal tumorto-normal brain ratio (TNR max , maximum tumor activity divided by mean of normal tissue) and MTV (volume of tumor tissue that shows uptake>1.3-fold of mean uptake in normal tissue) were measured on MET PET. Adult patients were classified into two subgroups according to Radiation Therapy Oncology Group Recursive Partitioning Analysis (RTOG RPA) classification. Prognostic values of TNR max , MTV and clinicopathologic factors were evaluated with regard to progression-free survival (PFS). Results Median PFS of all patients was 7.9 months (range 1.0-53.8 months). In univariate analysis, MTV (cutoff 35 cm 3 ) was a significant prognostic factor for PFS (P=0.01), whereas TNR max (cutoff 3.3) and RTOG RPA class were not (P=0.80 and 0.61, respectively). Treatment of surgical resection exhibited a borderline significance (P=0.06). In multivariate analysis, MTV was the only independent prognostic factor for PFS (P=0.03). Conclusion MTV on MET PET is a significant and independent prognostic factor for PFS in HGG patients, whereas TNR max is not. Thus, performing volumetric analysis of MET PET is recommended in HGG for better prognostication.

show abstract

High-grade glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Cited by 640 publications

References 70 publications

Association between small heat shock protein B11 and the prognostic value of MGMT promoter methylation in patients with high-grade glioma

Association between small heat shock protein B11 and the prognostic value of MGMT promoter methylation in patients with high-grade glioma

Modern tactics of treatment of malignant glyom of the brain and the case of the complete answer of the tumor on the background of the long-term reception of bevacizumab

Prognostic Value of Metabolic Tumor Volume on 11C-Methionine PET in Predicting Progression-Free Survival in High-Grade Glioma

Contact Info

Product

Resources

About